Overview

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the effect of Viracept in combination with modified antiretroviral therapy on the outcome of cutaneous and mucosal Kaposi's Sarcoma (KS).

Phase:

Phase 2

Details

Lead Sponsor:

Agouron Pharmaceuticals

Treatments:

Nelfinavir